HBMHF (HBM Holdings) Moat Score: 2/10 (As of Jul. 30, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HBMHF HBM Holdings Ltd HBMHF
73 GF Score
Price $1.56
GF Value $0.87
! 4 Warning Signs
View Full Analysis

What is HBM Holdings Moat Score?

HBM Holdings HBMHF 73 Moat Score is 2 as of Jul. 30, 2026. GuruFocus rates HBMHF with a GF Score™ of 73/100 and a GF Value™ of $0.87. The stock has 4 warning signs investors should review. Among 1,394 Biotechnology companies, HBM Holdings ranks better than 58.32% on this metric.

HBM Holdings has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

HBM Holdings has No Moat: HBM Holdings Ltd lacks significant market leadership or unique competitive advantages. The company does not exhibit strong brand strength, network effects, or significant customer switching costs. There are no notable intellectual properties or regulatory barriers that provide a durable competitive edge.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes HBM Holdings might have No Moat - Very weak/transient advantages.

HBM Holdings  (OTCPK:HBMHF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

HBM Holdings Moat Score Related Terms

HBMHF vs VRTX, REGN, RVMD: Moat Score Comparison

For the Biotechnology subindustry, HBM Holdings's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HBM Holdings Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HBM Holdings's Moat Score distribution charts can be found below:

* The bar in red indicates where HBM Holdings's Moat Score falls into.


HBMHF
73GF Score
HBM Holdings Ltd HBMHF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
HBM Holdings (HBMHF) has a Moat Score of 2 as of Jul. 30, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, HBM Holdings ranks #581 out of 1394 companies in the Biotechnology industry, placing it in the top 41.7%.
Is HBM Holdings' Moat Score too high?
HBM Holdings' current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. HBM Holdings' value of 2 is 0% at this industry median. Based on the distribution chart, HBM Holdings ranks #581 out of 1394 companies in the Biotechnology industry, which is above the industry midpoint. Overall, HBM Holdings has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does HBM Holdings' Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, HBM Holdings ranks #581 out of 1394 companies for Moat Score. This puts HBM Holdings in the upper half of its industry. The industry median Moat Score is 2.00. HBM Holdings' value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,394 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HBM Holdings's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HBM Holdings's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HBM Holdings stock overvalued right now?
HBM Holdings (HBMHF) has a current Moat Score of 2. The stock's GF Value™ is $0.87, compared to a current price of $1.56 — trading 79.3% above its estimated fair value. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. HBM Holdings' overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For HBM Holdings (HBMHF), the current Moat Score is 2 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HBM Holdings (HBMHF) Overvalued in 2026?

Based on GuruFocus' analysis, HBM Holdings stock appears to be overvalued. The current stock price of $1.56 is trading 79.3% above its estimated GF Value™ of $0.87.

Key valuation signals for HBMHF:

  • Moat Score: 2
  • GF Value™: $0.87 vs. price of $1.56 (79.3% above fair value)
  • GF Score™: 73/100 with 4 warning signs
  • Industry Position: 0% at the Biotechnology median (#581 of 1394)

No single metric tells the full story. See the HBMHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HBM Holdings Business Description

Other Exchanges 02142:Hong Kong6XY:Germany
Address No. 388 Fenglin Road, 6th Floor, Tower B, Fenglin International Phase I, Xuhui District, Shanghai, CHN, 200032
HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the Europe.
73GF Score

Get the complete analysis for HBMHF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.56
Price
$0.87
GF Value